Healthcare Professionals

The MCPHD offers a free asthma referral service

Services offered: 
Asthma education

Environmental assessment of the home, schools, workplace

Public Health Nurse

Smoking cessation

Social work

Nutritionist

Dietician covering Kids Medicaid/Hoosier Healthwise assistance

Education offered for topics such as:
   - Appropriate developmental tasks and expectations
   - Asthma action plan
   - Asthma self management
   - Adherence to asthma action plan
   - Home/work/school environment assessment
   - Peak flow monitoring
   - Trigger identification
   - Common symptoms and early detection
   - Socio-economic and psychosocial concerns
   - Safety issues

Current Self Medication Laws of Indiana  

Contract to Carry and Permission Form for School

Student Asthma Action Card  

Childcare Asthma Action Card

  About the Asthma Alliance of Indianapolis   

MDWise  

PRESTIGIOUS ASTHMA SOCIETIES SUPPORT FeNO MEASUREMENT

As the leader in the measurement of fractional exhaled nitric oxide (FeNO), Aerocrine is excited to announce that 2 prestigious asthma societies have formally endorsed FeNO measurement as a valuable tool for use in the assessment and management of asthma.

Last week, the American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) released a joint position statement¹ endorsing and supporting the American Thoracic Society’s (ATS) clinical practice guideline: Interpretation of Exhaled Nitric Oxide for Clinical Applications. The endorsement by the ACAAI and AAAAI underscores the importance of measuring FeNO to asses airway inflammation when determining appropriate treatment for patients with asthma.

The ATS guideline, which was published in September 2011, defines clinical situations in which FeNO testing is appropriate, as well as specific cut points to use when interpreting FeNO levels.² The ATS guideline, now endorsed by the AAAAI and ACAAI, notes that FeNO testing provides valuable information to the physican that traditional clinical tools cannot provide.

We appreciate your support and will keep you updated on future news about FeNO measurement via monthly e-mails and communication with your local Aerocrine representatives.

Please contact us should you have any further questions regarding this communication

If a friend forwarded you this e-mail and you would like to receive future e-mails from Aerocrine, you may subscribe here.

References: 1. Zitt M, Oppenheimer J, Bernstein D, et al; on behalf of the ACAAI/AAAAI Joint Work Group. AAAAI/ACAAI joint statement of support of the ATS clinical practice guideline: Interpretation of Exhaled Nitric Oxide for Clinical Applications. http://www.acaai.org/Documents/FeNOJointStatement3-6-12.pdf. Published February 1, 2012. Accessed April 2, 2012. 2. Dweik RA, Boggs PB, Erzurum SC, et al: on behalf of the American Thoracic Society Subcommittee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615.

NIOX MINO^®, NIOX^®, and Aerocrine are registered trademarks of Aerocrine AB.

View it in a browser | Update your profile | Unsubscribe | Subscribe | Forward to a friend

©2012 Aerocrine Inc
562 Central Avenue, New Providence, NJ 07974
www.aerocrine.com · www.nioxmino.com

Asthma Action Plan (Student)

  Asthma Action Plan (Childcare)